Education
About Us
Working with TipRanks
Follow Us
HAVN Life Sciences (HAVLF)
OTHER OTC:HAVLF
Total Valuation
HAVN Life Sciences has a market cap or net worth of $545.19K. The enterprise value is ―.
Market Cap$545.19K
Enterprise Value―
Share Statistics
HAVN Life Sciences has 25,646,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,646,020
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
HAVN Life Sciences’s return on equity (ROE) is -7.15 and return on invested capital (ROIC) is -313.24%.
Return on Equity (ROE)-7.15
Return on Assets (ROA)-5.53
Return on Invested Capital (ROIC)-313.24%
Return on Capital Employed (ROCE)-2.84
Revenue Per Employee46.08K
Profits Per Employee-3.74M
Employee Count6
Asset Turnover0.07
Inventory Turnover0.16
Valuation Ratios
The current PE Ratio of HAVN Life Sciences is ―. HAVN Life Sciences’s PEG ratio is 0.00035.
PE Ratio―
PS Ratio1.08
PB Ratio0.10
Price to Fair Value0.10
Price to FCF-0.04
Price to Operating Cash Flow-0.02
PEG Ratio0.00035
Income Statement
In the last 12 months, HAVN Life Sciences had revenue of 276.47K and earned -22.44M in profits. Earnings per share was -5.25.
Revenue276.47K
Gross Profit89.69K
Operating Income-9.81M
Pretax Income-22.44M
Net Income-22.44M
EBITDA-21.80M
Earnings Per Share (EPS)-5.25
Cash Flow
In the last 12 months, operating cash flow was -2.61M and capital expenditures 0.00, giving a free cash flow of -2.61M billion.
Operating Cash Flow-2.61M
Free Cash Flow-2.61M
Free Cash Flow per Share-0.10
Dividends & Yields
HAVN Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1981.20
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)0.00
Important Dates
HAVN Life Sciences upcoming earnings date is Dec 20, 2024, After Close (Confirmed).
Last Earnings DateSep 20, 2024
Next Earnings DateDec 20, 2024
Ex-Dividend Date―
Financial Position
HAVN Life Sciences as a current ratio of 4.51, with Debt / Equity ratio of 12.40%
Current Ratio4.51
Quick Ratio2.62
Debt to Market Cap0.00
Net Debt to EBITDA0.03
Interest Coverage Ratio-152.94
Taxes
In the past 12 months, HAVN Life Sciences has paid 64.14K in taxes.
Income Tax64.14K
Effective Tax Rate>-0.01
Enterprise Valuation
HAVN Life Sciences EV to EBITDA ratio is 0.02, with an EV/FCF ratio of 0.05.
EV to Sales-1.33
EV to EBITDA0.02
EV to Free Cash Flow0.05
EV to Operating Cash Flow0.05
Balance Sheet
HAVN Life Sciences has $13.99K in cash and marketable securities with $26.23K in debt, giving a net cash position of -$12.25K billion.
Cash & Marketable Securities$13.99K
Total Debt$26.23K
Net Cash-$12.25K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$0.52
Margins
Gross margin is 32.44%, with operating margin of -3548.44%, and net profit margin of -8117.81%.
Gross Margin32.44%
Operating Margin-3548.44%
Pretax Margin-8117.81%
Net Profit Margin-8117.81%
EBITDA Margin-7886.41%
EBIT Margin-8094.61%
Analyst Forecast
The average price target for HAVN Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―